{"nctId":"NCT01753570","briefTitle":"Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)","startDateStruct":{"date":"2012-12"},"conditions":["Chronic Hepatitis C(CHC)"],"count":74,"armGroups":[{"label":"MP-424+RBV+IFN beta, Genotype1","type":"EXPERIMENTAL","interventionNames":["Drug: MP-424","Drug: RBV(24 weeks)","Drug: IFN beta(24 weeks)"]},{"label":"RBV+IFN beta, Genotype1","type":"EXPERIMENTAL","interventionNames":["Drug: RBV(48 weeks)","Drug: IFN beta(48 weeks)"]},{"label":"MP-424+RBV+IFN beta, Genotype2","type":"EXPERIMENTAL","interventionNames":["Drug: MP-424","Drug: RBV(24 weeks)","Drug: IFN beta(24 weeks)"]}],"interventions":[{"name":"MP-424","otherNames":[]},{"name":"RBV(24 weeks)","otherNames":[]},{"name":"IFN beta(24 weeks)","otherNames":[]},{"name":"RBV(48 weeks)","otherNames":[]},{"name":"IFN beta(48 weeks)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Genotype 1 or 2, chronic hepatitis C, with depression(including the past)\n* Treatment-naïve(Genotype 1 only) or patient who have ever had previous IFN based treatment\n* Able and willing to follow contraception requirements\n\nExclusion Criteria:\n\n* Cirrhosis of the liver or hepatic failure\n* Hepatitis B surface antigen-positive or HIV antibodies-positive\n* History of, or concurrent hepatocellular carcinoma\n* History of, or concurrent serious depression, schizophrenia, or suicide attempt in the past\n* Pregnant, lactating, or suspected pregnant patients, or male patients whose female partner is pregnant","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Undetectable HCV (Hepatitis C Virus) RNA (Ribonucleic Acid) at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.3","spread":null},{"groupId":"OG001","value":"20.0","spread":null},{"groupId":"OG002","value":"71.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Undetectable HCV RNA at 4 Weeks After Beginning of Drug Administration (RVR, Rapid Viral Response)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.0","spread":null},{"groupId":"OG001","value":"6.7","spread":null},{"groupId":"OG002","value":"92.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Undetectable HCV RNA at Completion of Drug Administration (ETR, End-of-treatment Response)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.7","spread":null},{"groupId":"OG001","value":"30.0","spread":null},{"groupId":"OG002","value":"85.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Undetectable HCV RNA at 12 Weeks After Completion of Drug Administration","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null},{"groupId":"OG001","value":"20.0","spread":null},{"groupId":"OG002","value":"71.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Transition of Serum HCV RNA Levels","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.73","spread":null},{"groupId":"OG001","value":"6.83","spread":null},{"groupId":"OG002","value":"6.05","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.15","spread":null},{"groupId":"OG001","value":"5.65","spread":null},{"groupId":"OG002","value":"3.80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.35","spread":null},{"groupId":"OG001","value":"4.85","spread":null},{"groupId":"OG002","value":"2.80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.40","spread":null},{"groupId":"OG001","value":"5.30","spread":null},{"groupId":"OG002","value":"1.25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.30","spread":null},{"groupId":"OG001","value":"4.60","spread":null},{"groupId":"OG002","value":"0.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":null},{"groupId":"OG001","value":"3.70","spread":null},{"groupId":"OG002","value":"0.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":null},{"groupId":"OG001","value":"3.20","spread":null},{"groupId":"OG002","value":"0.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":null},{"groupId":"OG001","value":"2.75","spread":null},{"groupId":"OG002","value":"0.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":null},{"groupId":"OG001","value":"3.20","spread":null},{"groupId":"OG002","value":"0.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":null},{"groupId":"OG001","value":"6.20","spread":null},{"groupId":"OG002","value":"0.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":null},{"groupId":"OG001","value":"6.20","spread":null},{"groupId":"OG002","value":"0.50","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With the Emergence of Resistance-associated Variants After MP-424 Administration at the Non-structural 3 Protease Region of HCV.","description":"To examine the emergence of resistance-associated variants after MP-424 administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":30},"commonTop":["Pyrexia","Anaemia","Malaise","Headache","Blood uric acid increased"]}}}